Document Detail

Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha.
MedLine Citation:
PMID:  11032737     Owner:  NLM     Status:  MEDLINE    
We have previously reported that IFNalpha-chronic treatment for 41 days induced a partial phenotype reversion on HeLa cells along with a down-regulation of HPV18 mRNA levels. However, tumorigenicity of these cells in nude mice was unchanged. Interestingly, after 1 year of IFNalpha-chronic exposition, HeLa cells failed to induce s.c. tumors when injected into nude mice. In such experimental conditions both HPV18 DNA integration pattern and viral DNA copy number present in HeLa cells remained intact in the nontumorigenic phenotype cells. As result of the treatment with IFNalpha, HeLa cells rendered more resistant to lysis mediated by activated natural killer cells in vitro. Furthermore, IFNalpha-chronic treatment was able to induce VEGF and decrease bFGF mRNA expression, suggesting a potential effect on the angiogenic behavior of these tumoral cells. Thus, long-term treatment of HeLa cells with IFNalpha can accomplish a reversion of the malignant phenotype by a sequential multistep mechanism, in which the antiangiogenic effect of IFNalpha could be one of the contributing events.
O López-Ocejo; S E Perea; M Bequet-Romero; M J Araña; P López Saura
Related Documents :
12908087 - Sensitivity of chronically hiv-1 infected hela cells to electrical stimulation.
14704127 - Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis.
1336207 - Herpes simplex virus induces unscheduled dna synthesis in virus-infected cervical cance...
1382917 - D-glyceraldehyde-3-phosphate dehydrogenase from hela cells--2. immunological characteri...
18682937 - Cellular uptake of pet tracers of glucose metabolism and hypoxia and their linkage.
23759587 - Predicting therapy response in live tumor cells isolated with the flexible micro spring...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  277     ISSN:  0006-291X     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-11-06     Completed Date:  2000-11-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  410-6     Citation Subset:  IM    
Copyright Information:
Copyright 2000 Academic Press.
Division of Vaccine, Center for Genetic Engineering and Biotechnology, C. Havana, Cuba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blotting, Northern
Blotting, Southern
Cell Survival / drug effects
Endothelial Growth Factors / biosynthesis
Fibroblast Growth Factor 2 / biosynthesis
Gene Dosage
Hela Cells
Interferon Alfa-2b / pharmacology*
Interferon-alpha / pharmacology*
Killer Cells, Natural / metabolism
Lymphokines / biosynthesis
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Neovascularization, Pathologic*
Papillomaviridae / chemistry,  metabolism
RNA, Messenger / metabolism
Recombinant Proteins / pharmacology
Time Factors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Reg. No./Substance:
0/Endothelial Growth Factors; 0/Interferon-alpha; 0/Lymphokines; 0/RNA, Messenger; 0/Recombinant Proteins; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 103107-01-3/Fibroblast Growth Factor 2; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  cDNA representational difference analysis of human neutrophils stimulated by GM-CSF.
Next Document:  Glibenclamide acts as an inhibitor of acyl-CoA:cholesterol acyltransferase enzyme.